INOSITOL

US Previously Marketed

First approved in 1949

Details

Stereochemistry	ACHIRAL
Molecular Formula	C6H12O6
Molecular Weight	180.1559
Optical Activity	UNSPECIFIED
Defined Stereocenters	6 / 6
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1O

InChI

InChIKey=CDAISMWEOUEBRE-GPIVLXJGSA-N

InChI=1S/C6H12O6/c7-1-2(8)4(10)6(12)5(11)3(1)9/h1-12H/t1-,2-,3-,4+,5-,6-

HIDE SMILES / InChI

Description
Sources: http://www.rxlist.com/inositol/supplements.htm
Curator's Comment: description was created based on several sources, including: http://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/SCOGS/ucm260436.htm

Inositol is a vitamin-like substance. It is found in many plants and animals. It is produced by the human body from glucose, it is not an essential nutrient. Inositol and some of its mono- and polyphosphates function as the basis for a number of signaling and secondary messenger molecules. Inositol is used for diabetic nerve pain, panic disorder, high cholesterol, insomnia, cancer, depression, schizophrenia, Alzheimer’s disease, attention deficit-hyperactivity disorder (ADHD), autism, promoting hair growth, a skin disorder called psoriasis, and treating side effects of medical treatment with lithium. Inositol is also used by mouth for treating conditions associated with polycystic ovary syndrome, including failure to ovulate; high blood pressure; high triglycerides; and high levels of testosterone. Inositol is possibly safe for most adults. It can cause nausea, tiredness, headache, and dizziness.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Serotonin 2 (5-HT2) receptor 87 Target ID: CHEMBL2095200 Sources: http://www.ncbi.nlm.nih.gov/pubmed/11163636	Activator 1430

Conditions

Condition	Modality	Highest Phase	Product
Panic disorder 22 Sources: http://www.rxlist.com/inositol/supplements.htm http://dmpharma.co.in/Myo-inositol,L-methyl%20Folate%20Calcium%20and%20Vitamin%20D3%20Tablets.html	Primary	Phase I 428	MYOFORT-3G Approved Use Unknown
Obsessive-compulsive disorder 28 Sources: http://www.rxlist.com/inositol/supplements.htm http://dmpharma.co.in/Myo-inositol,L-methyl%20Folate%20Calcium%20and%20Vitamin%20D3%20Tablets.html	Primary	Phase I 428	MYOFORT-3G Approved Use Unknown
Polycystic ovary syndrome 2 Sources: http://www.rxlist.com/inositol/supplements.htm	Primary	Approved 8429	MYOFORT-3G Approved Use GRAS. The formula is useful in polycystic ovary syndrome treatment.

PubMed

Title	Date	PubMed
Highly active antiretroviral therapy reverses brain metabolite abnormalities in mild HIV dementia.	1999 Sep 11	10489041
Metabolic relations of inositol 3,4,5,6-tetrakisphosphate revealed by cell permeabilization. Identification of inositol 3,4,5, 6-tetrakisphosphate 1-kinase and inositol 3,4,5,6-tetrakisphosphate phosphatase activities in mesophyll cells.	2000 Apr	10759517
Prolonged inactivation of nicotinic acid adenine dinucleotide phosphate-induced Ca2+ release mediates a spatiotemporal Ca2+ memory.	2001 Apr 6	11139579
Human platelets bind and degrade 2-arachidonoylglycerol, which activates these cells through a cannabinoid receptor.	2001 Feb	11168423
Clinical usefulness of measuring urinary polyol excretion by gas-chromatography/mass-spectrometry in type 2 diabetes to assess polyol pathway activity.	2001 Feb	11165691
2-Aminoethoxydiphenyl borate affects the inositol 1,4,5-trisphosphate receptor, the intracellular Ca2+ pump and the non-specific Ca2+ leak from the non-mitochondrial Ca2+ stores in permeabilized A7r5 cells.	2001 Feb	11162848
Adenosine triphosphate-evoked cytosolic calcium oscillations in human granulosa-luteal cells: role of protein kinase C.	2001 Feb	11158045
Hydrogen peroxide induces Src family tyrosine kinase-dependent activation of Xenopus eggs.	2001 Feb	11148452
Inositol 1,4,5-trisphosphate receptor isoform expression in mouse pancreatic islets: effects of carbachol.	2001 Feb 1	11172737
Calcium currents and arrhythmias: insights from molecular biology.	2001 Feb 1	11165554
Rapid down-regulation of the type I inositol 1,4,5-trisphosphate receptor and desensitization of gonadotropin-releasing hormone-mediated Ca2+ responses in alpha T3-1 gonadotropes.	2001 Feb 2	11069921
Mapping of the ATP-binding sites on inositol 1,4,5-trisphosphate receptor type 1 and type 3 homotetramers by controlled proteolysis and photoaffinity labeling.	2001 Feb 2	11035010
The effects of inositol treatment in animal models of psychiatric disorders.	2001 Jan	11172878
An altered peptide ligand inhibits the activities of matrix metalloproteinase-9 and phospholipase C, and inhibits T cell interactions with VCAM-1 induced in vivo by a myasthenogenic T cell epitope.	2001 Jan	11149906
Magnetic resonance spectroscopy of brain hemangiopericytomas: high myoinositol concentrations and discrimination from meningiomas.	2001 Jan	11147898
Ca(2+) mobilization, tyrosine hydroxylase activity, and signaling mechanisms in cultured porcine adrenal medullary chromaffin cells: effects of leptin.	2001 Jan	11145592
Physiological and morphometric analyses of neuropathy in sucrose-fed OLETF rats.	2001 Jan	11137177
A Salmonella inositol polyphosphatase acts in conjunction with other bacterial effectors to promote host cell actin cytoskeleton rearrangements and bacterial internalization.	2001 Jan	11136447
PI-3 kinase and IP3 are both necessary and sufficient to mediate NT3-induced synaptic potentiation.	2001 Jan	11135641
Reactive oxygen species mediate alpha-adrenergic receptor-stimulated hypertrophy in adult rat ventricular myocytes.	2001 Jan	11133229
ANG II potentiates mitogenic effect of norepinephrine in vascular muscle cells: role of FGF-2.	2001 Jan	11123223
Low level of sarcolemmal phosphatidylinositol 4,5-bisphosphate in cardiomyopathic hamster (UM-X7.1) heart.	2001 Jan	11121803
Heterogeneity of calcium stores and elementary release events in canine pulmonary arterial smooth muscle cells.	2001 Jan	11121373
Extracellular mechanism through the Edg family of receptors might be responsible for sphingosine-1-phosphate-induced regulation of DNA synthesis and migration of rat aortic smooth-muscle cells.	2001 Jan 1	11115407
Constitutive signaling of the human cytomegalovirus-encoded chemokine receptor US28.	2001 Jan 12	11050102
Molecular cloning and characterization of a novel regulator of G-protein signaling from mouse hematopoietic stem cells.	2001 Jan 12	11042171
Traumatic injury of cortical neurons causes changes in intracellular calcium stores and capacitative calcium influx.	2001 Jan 19	11050103
A novel bifunctional phospholipase c that is regulated by Galpha 12 and stimulates the Ras/mitogen-activated protein kinase pathway.	2001 Jan 26	11022047
Alternative splice variants of hTrp4 differentially interact with the C-terminal portion of the inositol 1,4,5-trisphosphate receptors.	2001 Jan 5	11163362
Identification of cyclic ADP-ribose-dependent mechanisms in pancreatic muscarinic Ca(2+) signaling using CD38 knockout mice.	2001 Jan 5	11001947
The antidepressant activity of inositol in the forced swim test involves 5-HT(2) receptors.	2001 Jan 8	11163636
Regulation of slow wave frequency by IP(3)-sensitive calcium release in the murine small intestine.	2001 Mar	11171626
Characterization and mapping of the 12 kDa FK506-binding protein (FKBP12)-binding site on different isoforms of the ryanodine receptor and of the inositol 1,4,5-trisphosphate receptor.	2001 Mar 1	11171121
Rational design of a peptide agonist that interacts selectively with the orphan receptor, bombesin receptor subtype 3.	2001 Mar 23	11112777
Stereospecificity of myo-inositol hexakisphosphate dephosphorylation by a phytate-degrading enzyme of Escherichia coli.	2001 Nov 17	11035187

Patents

Sample Use Guides

In Vivo Use Guide

For panic disorder: 12 to 18 grams per day. For obsessive-compulsive disorder: inositol 18 grams per day. For treating symptoms associated with polycystic ovary syndrome: D-chiro-inositol 1200 mg per day. For treating lithium-related psoriasis: 6 grams daily.

Route of Administration: Oral

In Vitro Use Guide

The kinetics of germinal vesicle breakdown after 4 h of incubation was significantly higher in oocytes incubated with 30 mmol/l of myo-inositol than in controls (P < 0.001).

Name

Type

Language

INOSITOL

Official Name

English

INOSITOL [FCC]

Common Name

English

Inositol [WHO-DD]

Common Name

English

INOSITOL [VANDF]

Common Name

English

INOSITOL [MI]

Common Name

English

inositol [INN]

Common Name

English

I-INOSITOL

Common Name

English

1,2,3,5-TRANS-4,6-CYCLOHEXANEHEXOL, CIS-

Common Name

English

NSC-25142

Code

English

NSC-55551

Code

English

INOSITOL [USAN]

Common Name

English

INOSITOL, MYO-

Common Name

English

NSC-404118

Code

English

MYO-INOSITOL [EP MONOGRAPH]

Common Name

English

CIS-1,2,3,5-TRANS-4,6-CYCLOHEXANEHEXOL

Common Name

English

NSC-8101

Code

English

INOSITOL [MART.]

Common Name

English

INOSITOL [USP-RS]

Common Name

English

INOSITOL, MYO

Common Name

English

INOSITOL [INCI]

Common Name

English

myo-Inositol

Common Name

English

Classification Tree Code System Code

WHO-ATC

A11HA07